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Glycans are key players in many biological processes. They are essential for protein folding and stability
and act as recognition elements in cell–cell and cell–matrix interactions. Thus, being at the heart of medi-
cally relevant biological processes, glycans have come onto the scene and are considered hot spots for
biomedical intervention. The progress in biophysical techniques allowing access to an increasing molecular
and structural understanding of these processes has led to the development of effective therapeutics. In-
deed, strategies aimed at designing glycomimetics able to block specific lectin–carbohydrate interactions,
carbohydrate-based vaccines mimicking self- and non-self-antigens as well as the exploitation of the ther-
apeutic potential of glycosylated antibodies are being pursued. In this mini-review the most prominent
contributions concerning recurrent diseases are highlighted, including bacterial and viral infections, cancer
or immune-related pathologies, which certainly show the great promise of carbohydrates in drug
discovery.
Introduction
Glycans are essential biomolecules in nature. They can be
found as simple monosaccharides or forming more complex
structures such as naturally occurring glycoconjugates, where
the sugar moieties are attached to proteins or lipids. Being
the most abundant molecules in living organisms, carbohy-
drates play many important biological roles, including their
function as an energy source through glucose metabolism or
as a structural component of cell walls.1 It is noteworthy that
the biological roles of glycans go further beyond.2 Complex
glycans are required for the proper folding of newly synthe-
sized polypeptides and are involved in the stability, solubility
and trafficking of the final glycoproteins. Moreover, being at
the surface of all types of cells, carbohydrates drive critical
biological functions that rely on the specific recognition of
glycan structures by other biomolecules (Fig. 1). These inter-
actions are fundamental and trigger important processes in-
cluding cell signalling, proliferation and differentiation or
tissue development. Indeed, the molecular recognition of gly-
cans is at the heart of pathological processes such as bacterial
adhesion, viral infection, inflammation or immune system ac-
tivation.3 Consequently, either involved in self- or non-self-
recognition, glycans are attractive targets for a wide range of
medical applications. In fact, carbohydrates are more and
more recognized as hot spots for biomedical intervention in
drug discovery programs. However, in balance with their bio-
logical roles, the exploitation of sugars as biomedical targets
has been poorly developed. Certainly, the molecular basis
governing glycan functions is still not fully understood, prob-
ably as a consequence of the huge structural complexity and
heterogeneity of glycans.
The wide variety of monosaccharides which can be differ-
ently linked, together with the non-template driven glycan
biosynthesis, increases the number of glycan structures pres-
ent in nature. In fact, glycosylation in life is a complex pro-
cess which varies among different cells and tissues and is
affected by cell microenvironment.4,5 These factors have hin-
dered the methodological evaluation of the glycome and have
slowed down the progress in glycosciences.6 Nonetheless, ad-
vances in glycan synthesis and the development of highly
sensitive and informative analytical tools are providing in-
creasing knowledge in the complex correlation between gly-
can structure and function. The progress in MS instrumenta-
tion allows mapping of glycan attachment sites, profiling
glycan structural variations, and determining detailed fine
structures of carbohydrates.7 In addition, new synthetic strat-
egies have allowed access to pure and high amounts of de-
fined complex glycan structures.8 The combination of these
novel synthetic approaches with high-throughput screening
methods, such as those based on microarrays,9 has become a
potent tool for the discovery of glycan receptors and the study
of structure–activity relationships. Moreover, the progress in
high-resolution techniques including NMR, X-ray or EM has
revealed fine structural details controlling glycan recognition.
1678 | Med. Chem. Commun., 2019, 10, 1678–1691 This journal is © The Royal Society of Chemistry 2019
a CIC bioGUNE, Bizkaia Technology Park, Building 800, 48162 Derio, Bizkaia,
Spain. E-mail: jjbarbero@cicbiogune.es
b CIC biomaGUNE, Paseo Miramon 182, 20014 Donostia, Gipuzkoa, Spain
c Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Bizkaia, Spain
dDepartment of Organic Chemistry II, University of the Basque Country, UPV/
































































































View Journal  | View Issue
Med. Chem. Commun., 2019, 10, 1678–1691 | 1679This journal is © The Royal Society of Chemistry 2019
In parallel, computational tools are being developed for the
refinement of X-ray crystal structures containing glycans10
and the revolution in electron imaging methods approaching
atomic resolution has provided access to glycoconjugate im-
ages.11 Similarly, technical advances in sensitivity and resolu-
tion and the use of labelling strategies have allowed address-
ing NMR studies of large saccharides that provide a much
more accurate 3D view of the glycan structure and conforma-
tion.12 Moreover, specific NMR experiments including STD-
NMR, trNOESY or those focused on protein-based methods
have been successfully designed to characterize glycan inter-
actions in solution.13 Major endeavours are being applied to
study these interactions under mimicked physiological condi-
tions14,15 or even using living cells.16 The growing under-
standing of structure–activity relationships is triggering a
boost in the application of glycans in medicinal chemistry.
We and others have reviewed the most prominent contribu-
tions to the design of glycomimetics, glycan-based vaccines
and therapeutics and highlighted the great promise of carbo-
hydrates in drug discovery.17 This non-exhaustive review also
aims to show the recent advances in the field over the past
years, which definitely show the biomedical relevance of car-
bohydrates. Small molecule glycomimetics, glycopeptides and
glycoproteins as well as a brief description of carbohydrate-
based vaccines are included.
Small molecule glycomimetics
Heparin and mimetics. Heparin is the oldest
carbohydrate-based drug in the market and is one of the most
prescribed drugs described today as anticoagulant.18 Heparin
binds and activates antithrombin, a protease inhibitor of the
coagulation cascade; however, the structural heterogeneity of
heparins is fairly known and may entail potential problems
associated to the purity and safety of commercial heparin-
based drugs.19 Thus, their undesired pharmacokinetic proper-
ties, low oral absorption and side effects have exhaustively
promoted searching for glycomimetics with improved fea-
tures.20 In 2001, GlaxoSmithKline registered fondaparinux as
a new antithrombin drug called Arixtra,21 a glycomimetic
which was designed using the natural pentasaccharide se-
quence responsible for the activity of heparin as template
(Scheme 1). Other potential applications of heparin, heparan
sulfate and chondroitin sulfate proteoglycans have also been
investigated.22 In this regard, the pentasaccharide fondaparinux
is one of the candidates proposed as a therapeutic ligand for
targeting the leukocyte common antigen-related protein (LAR),
a type IIa protein tyrosine phosphatase (RPTP) involved in sev-
eral neuron processes like axon extension and regeneration.23
Fondaparinux is a particular case of a structurally well-
defined heparin,24 but as mentioned above, heparins are gen-
erally polydisperse drugs prepared from animal tissues.25 Re-
search is still pursuing the development of efficient synthetic
methodologies to produce monodisperse heparin oligosaccha-
rides in large scale, both natural fragments and modified scaf-
folds. In fact, notable advances are enabling the synthesis and
evaluation of new heparin-like fragments as potential thera-
peutics. The incorporation of one-pot-based strategies26 and it-
erative synthetic schemes has permitted an easier and faster
access to very large heparin-like oligomers.27 Moreover, the
programmed inclusion of different protective groups at specific
positions allows further modifications of the original macro-
molecules.28 Some of these modifications also include heparin
labelling to facilitate the purification steps29 or tagging to mon-
itor the tissue distribution of heparin-based therapeutic candi-
dates in biological studies.30 Additionally, enzymatically driven
protocols have allowed the synthesis of large libraries of hepa-
rin oligosaccharides ranging from 6 to 9 sugar units and with
different sulfation patterns.31 Also, monodisperse heparin sul-
fate with anticoagulant activity has been directly prepared in
human cells by recombinant expression of human serglycin.32
All these methodologies have permitted a thorough analysis of
those structural factors affecting heparin binding to relevant
biomedical targets, especially the position/distribution or
amount of sulfate groups in the heparin scaffold. Precise atten-
tion has been paid to the interaction of heparin fragments
with tau, β-amyloid and α-synuclein aggregates,33 the pro-
angiogenic cytokines VEGF165 and FGF-2,34 the chemokines
CXCL8 and CXCL12 (ref. 35) or the Robo1 receptor.36
Fig. 1 Three main biological roles of glycans as (A) energy source, (B) structural elements and (C) molecular recognition elements in cell–cell and
cell-pathogen interactions.
Scheme 1 Chemical structure of fondaparinux sodium salt,
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Targeting pathogen glycan receptors. Nowadays, the most
successful drugs based on sugar moieties are probably the
antiviral compounds zanamivir (Relenza) and oseltamivir
(Tamiflu). Both compounds are competitive neuraminidase li-
gands which are able to block the enzyme binding site and
prevent the release of the virus particle from the host cell.
Among pathogen infection mechanisms, bacteria commonly
resort to the recognition of host glycans by cell-surface
adhesins.37 Thus, glycomimetics able to interfere with or block
this interaction have been designed as antagonists of micro-
bial adhesion. The pathogen Pseudomonas aeruginosa,
infecting lung immunocompromised patients, employs its
lectins LecA and LecB (also called PA-IL and PA-IIL, respec-
tively) as virulence factors and biofilm building blocks. Thus,
these receptors represent significant therapeutic targets for
anti-adhesive treatment, and compounds aimed at competing
with human glycoconjugates have been developed. Indeed, the
tetrameric structure of LecA and LecB, with pairing of neigh-
boring binding sites at 29 Å and 41 Å,38 respectively, has stim-
ulated the design of multivalent templates as anti-pathogenic
agents.39–41 Additionally, key insights have been gained over
extensive structural studies allowing access to potent monova-
lent small molecules.42 For instance, C-glycoside nM inhibi-
tors bearing sulfonamide aglycones at the C6 position have
been reported for LecB (Fig. 2).43 Moreover, these compounds
displayed important drug-like properties such as good oral
bioavailability, metabolic stability and low toxicity.
While LecB displays strong affinity for Fuc-containing oli-
gosaccharides, LecA is a galactose-specific lectin. The system-
atic analysis of monofluorinated galactopyranosides where
the hydroxyl groups of the natural sugar were replaced one
by one allowed establishing the fundamental sugar inter-
acting features and provided the basis for designing potent
and stable glycomimetics for LecA.44 Interestingly, Titz and
coworkers have reported a covalent inhibitor bearing an
electrophilic epoxide, which exploits the reactivity towards a
specific cysteine residue on the carbohydrate binding domain
of the protein. This irreversible covalent bond with LecA per-
manently blocks the protein activity (Fig. 3).45
Among bacterial diseases, one of the most widely occurring
infections results from the interaction between FimH, a lectin
located at the tip of bacterial type 1 pili, and mannosylated
glycoproteins on the urothelial mucosa. The first crystal struc-
ture of FimH bound to butyl mannose was described in 2005
and established the basis for sugar binding.46 The mannose
is located in a deep pocket surrounded by hydrophobic resi-
dues (also known as tyrosine gate), whose architecture has
been exploited to design potent inhibitors. In fact, com-
pounds bearing aliphatic or aromatic aglycones attached to
α-D-Man have been synthesized and evaluated as potential
drugs.47 The use of fluorinated aglycones, which maximize
π–π stacking with the tyrosine gate, provided low nM antago-
nists with the best affinities reported to date (Fig. 4).48 In ad-
dition, prodrugs with improved oral bioavailability were also
obtained by phosphorylation of FimH antagonists.49
Traditionally, common strategies for the design of potent
glycomimetics have been focused on enhancing the contribu-
tion of the binding enthalpy by increasing the number and
strength of protein–ligand interactions, thus providing higher
affinities. However, this conception is changing in medicinal
chemistry and it is moving towards the further analysis of
the binding entropy contribution. In the case of FimH antag-
onists, septanose glycomimetics provided much the same
H-bond network as that of their parent hexoses but suffered
from entropic penalties due to the rigidification of the mole-
cule upon binding.50 Furthermore, tools such as KinITC have
recently emerged for evaluating the binding kinetics, parame-
ters which have been usually neglected.51
Targeting human glycan receptors. Relevant discovered
glycan-related drugs also include those targeting human
lectins such as the selectin inhibitors rivipansel and
uproleselan. Both molecules are in late-stage trials for the
treatment of sickle cell anemia and acute myeloid leukemia,
Fig. 2 C-glycoside inhibitors of LecB bearing sulfonamide moieties. X-ray
crystal structures of the interaction with LecB (pdb 5MB1 and 5MAY).
Fig. 3 Covalent inhibitor described for LecA. The crystal structure for
the non-covalent mode interaction is depicted (pdb 5MIM).
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respectively, and these examples demonstrate the success of
the rationally designed driven approach applied to the discov-
ery of selectin ligands. Selectins are cell surface lectins that
bind to sialyl Lewisx (sLex) antigens, mediate cell adhesion
and play a key role in inflammatory processes (Fig. 5).
The discovery of new potent inhibitors is an active area of
research. Ernst and co-workers used an NMR-guided frag-
ment screening for designing nM affinity E-selectin inhibi-
tors based on the attachment of the sLex scaffold, which
binds to the primary binding site, to a second site ligand.52
Additional strategies based on the use of glycopolymers with
a multivalent presentation of sLex or the single sugars Fuc,
Gal, or Neu5Ac have also provided very promising results for
inhibiting E-, P- and L-selectins.53 Other lectins such as DC-
SIGN, Siglecs and galectins, with important functions in in-
flammation or immune system activation, have also been
considered as important targets. Sialic acid sugars, working
as ligands of the immunosuppressive sialic acid binding
immunoglobulin-like (Siglec) lectins, are emerging as impor-
tant regulators of the immune system. Aberrant sialic acid–
Siglec interactions have been associated with multiple dis-
eases including autoimmunity, infection, inflammation, ag-
ing or cancer. Therefore, glycomimetics targeting Siglecs have
been pursued, especially for Siglec-2 (also called CD22).54
Sialoside mimetics carrying modifications on C-2, C-4, C-5
and C-9 of the sialic acid molecule were firstly envisaged, but
later multiple site modifications led to more potent inhibi-
tors.55 However, most of these glycomimetics do not have
enough avidity to compete with natural glycoprotein li-
gands,56 and thus, multivalent presentation on polymers or
nanoparticles provided more successful results.57 Interest-
ingly, Paulson and co-workers have designed Siglec ligands
based on di- and trivalent natural N-glycan scaffolds which
showed low nM/high pM avidity and were capable of being
endocytosed by CD22 on B lymphoma cells (Fig. 6).58 Feasi-
bly, the individual branches of the chemically modified
N-glycans interact simultaneously with multiple CD22 recep-
tors, increasing the binding affinity.
Single protein–carbohydrate interactions are usually weak
and therefore chemical strategies must be applied to enhance
the efficacy of glycomimetics. This is the case of the interac-
tion between DC-SIGN and its natural ligands. DC-SIGN is a
human C-type lectin receptor (CLR) located on the surface of
dendritic cells that recognizes Lewis-type and high-mannose
antigens. DC-SIGN introduces tolerance against self-antigens
but also recognizes antigens from numerous pathogens (HIV,
Ebola), a process that initiates an immune response or re-
sults in propagation and escape from the immune system.
The structural features of the binding between natural
sugars, including the blood type antigens and DC-SIGN, have
been explored59 and revealed that the development of high-
affinity ligands towards DC-SIGN has to overcome several
drawbacks: the low affinity of the monovalent binding events,
usually in the mM range, and the cross-reactivity among
CLRs. Hence, considerable efforts have been made to develop
high-affinity and selective glycomimetics. Indeed, approaches
based on targeting extended binding sites have been investi-
gated recently so as to improve the binding affinity. Although
the strategy has not been applied yet to the design of potent
DC-SIGN inhibitors, a library of 986 fragments has been scre-
ened using SPR, and five unknown secondary binding sites
were validated using 1H-15N HSQC NMR spectroscopy.60
Interestingly, the understanding of key binding structural fea-
tures was successfully exploited for designing highly specific
glycomimetics for DC-SIGN.61 The rational modification of
first-generation glycomimetics based on dimannosides pro-
vided μM affinity inhibitors that specifically recognize DC-
SIGN vs. langerin, a similar CLR. Structural studies indicated
that the introduction of a positive group on position C6 of
the interacting sugar would reduce the affinity for langerin,
since the stabilizing contacts with K313 on the binding site
Fig. 5 Chemical structure of selectin inhibitors rivipansel and uproleselan.
The chemical structure of sLex antigen and the crystal structure of the
interaction with selectin are depicted at the bottom (pdb 1G1T).
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of the protein would be abolished. In fact, the introduction
of a positively charged amino group in this position en-
hanced the affinity and selectivity towards DC-SIGN (Fig. 7A).
Notably, the structure of this compound is still far from
that of an ideal drug-like molecule. Indeed, the affinity should
be much more increased. The structurally open and water-
exposed binding domain of DC-SIGN has hampered the devel-
opment of potent glycomimetics and in fact, multivalency has
been resorted to in order to increase the binding affinity
(Fig. 7B).62 Recently, quantum dots surrounded by a dense ar-
ray of mono- and disaccharides have been used as probes to
gain insights into the binding mode of these multivalent in-
teractions.63 Galectins, which comprise a large family of β-D-
galactoside-binding lectins, are also involved in many biologi-
cal functions with important implications in cancer progres-
sion, inflammation, immune responses, fibrosis and heart
diseases.64 In fact, the blockage of galectins by high-potency
glycomimetics is being pursued as a therapeutic strategy65
and several related clinical trials are currently ongoing.66,67 A
huge effort has been made on the synthesis of mono- and
multivalent glycomimetics68 allowing access to promising
galectin ligands.69 In addition, the structural binding features
of galectins have been deeply investigated. We have recently
demonstrated how ligand flexibility modulates the thermody-
namics and kinetics of the protein–sugar binding process.70
Particularly, we found that histo blood group antigens, which
are quite rigid, bind to human galectin-3 with improved affin-
ity due to their more favourable entropy of binding.
Concerning this issue, a TF-mimetic with rather restricted
conformational flexibility that efficiently binds to galectin-3
with a significant gain on the binding entropy has been re-
cently reported.71 Moreover, recent neutron crystallography
studies of galectin-3 provided a detailed view of the
H-bonding network in the binding site of the protein.72 In
particular, for galectin-3, the introduction of aromatic groups
on the galactose C3 position of lactose, which established ad-
ditional favourable cation–π interactions with the protein,
provided potent compounds.73 Moreover, studies with aro-
matic thiodigalactoside derivatives, with improved hydrolytic
stability, yielded a low nanomolar inhibitor,74 TD139,75 which
has been approved by the US Food and Drug Administration
for the treatment of idiopathic pulmonary fibrosis. Subse-
quent structurally driven tuning of these molecules provided
selective and potent nM inhibitors.76–78 The introduction of
highly fluorinated aryltriazole groups on C3 favoured the in-
teractions with the protein, reaching KD values under 1–2 nM.
In fact, this strategy has recently led to the development of
aminopyrimidine–galactose hybrids with enhanced selectivity
(>300-fold) towards galectin-3 over galectin-1.79 Similarly, the
use of asymmetrical thiodigalactosides with C3-aryltriazolyl
and O3-coumaryl groups has also led to high-affinity and se-
lective galectin-3 inhibitors (Scheme 2).80
Therapeutic glycopeptides
Glycopeptide antibiotics (GPAs) such as vancomycin,
teicoplanin, bleomycin and ristocetin were discovered a long
time ago. However, more than 50 years after it was first intro-
duced, vancomycin still constitutes a standard therapy against
serious Gram-positive infections. In fact, the development of
new antibiotic glycopeptides is still a current area of re-
search.81 The general mechanism of action of glycopeptides
such as vancomycin entails the binding to lipid II inhibiting
the synthesis of peptidoglycans, a vital structural component
of the bacterial cell wall. Although the sugar moiety does not
participate in the direct contacts between vancomycin and
lipid II, it plays a key role in the back-to-back dimerization of
vancomycin that increases its lipid II binding affinity.82 More-
over, it has been suggested that the sugar residue provides
steric hindrance and limits the conformational flexibility of
the vancomycin molecule, driving it toward lipid II binding.83
Indeed, peptide or protein glycosylation exponentially ex-
pands the structure and biological functions of the
Fig. 7 (A) First- and second-generation DC-SIGN glycomimetics. The X-ray
crystal structure of DC-SIGN bound to a second-generation glycomimetic is
also represented (pdb 2XR5). (B) DC-SIGNmultivalent ligand.
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corresponding glycoconjugate. Factors such as the shape of
the interacting glycopeptide or glycoprotein, the glycan
density or additional carbohydrate-independent interactions
modulate their solubility, stability and molecular recogni-
tion.84 However, the complexity and heterogeneity of the gly-
cosylation process in natively expressed glycoproteins has
hampered the complete understanding of those effects modu-
lating their biological functions. Consequently, the synthetic
preparation of homogeneous glycopeptides and glycoproteins
has been pursued and allows extension of the overview be-
yond the “elemental” sugar–protein recognition phenomenon.
In fact, synthetic glycopeptides also known as
neoglycopeptides, capable of imitating the multivalent display
of carbohydrates at the cell surface, have become an impor-
tant objective as therapeutic compounds, and several reports
appeared in the past years about targeting medically relevant
lectins.85 Glycopeptide dendrimers,86 glycopeptide nano-
particles87 or glycopolyproline scaffolds88 have been success-
fully designed to enhance lectin avidity.
HIV glycopeptide antigens. Synthetic glycopeptides mim-
icking natural HIV envelope glycoproteins have also been en-
visaged as anti-HIV therapy. Viral envelope glycoproteins at
the surface of several viruses are targets for virus neutraliza-
tion. These proteins, such as gp120 in HIV-1, are decorated
with high-mannose-type glycans, which are the first structures
to be encountered by the host immune system. While these
N-glycans are recognized as self-antigens and help to evade
neutralization, much more potent antigenic responses can be
obtained targeting both internal glycans and the protein sur-
face. Hence, mimicking glycopeptides can be envisaged as a
therapeutic strategy to elicit a broad antibody response. This
approach was used by Wang and co-workers for the design
and synthesis of glycopeptides which induced immune re-
sponse against gp120.89 The minimal binding epitope was de-
termined by analyzing the antibody binding affinity in a panel
of V3 glycopeptides chemoenzymatically synthesized. The
study indicated that a 33-mer V3 glycopeptide carrying a high-
mannose N-glycan at the N332 site is highly immunogenic
(Fig. 8). Later studies with synthetic V3 N334 glycopeptides,
including a mutation found in HIV isolates, showed its im-
munogenicity against gp120 and gp140 envelope glycopro-
teins.90 Also, a similar approach using modified envelope tri-
mers has recently permitted the design of a novel
immunogen (RC1) that efficiently stimulates the production
of broadly neutralizing antibodies (bNAbs) by B cells.91 The
RC1 architecture includes the key deletion of the N156 glyco-
sylation site that gives rise to some structural changes without
affecting its affinity.
Mucin glycopeptide antigens. The transmembrane mucin
protein MUC1, which is overexpressed in many prevalent can-
cers, has also generated a lot of interest in the past recent
years as a promising target. MUC1 is densely glycosylated in
normal cells, but it is aberrantly glycosylated in tumour-
related cells presenting truncated glycan antigens (Tn, α-O-
GalNAc-Ser/Thr; T, α-O-Galβ1-3GalNAc-Ser/Thr), and prema-
ture sialylation (sialyl-Tn and sialyl-T). Thus, specific antigens
are exposed to the immune system, such as the peptide back-
bone or TACAs (tumor associated carbohydrate antigens),
making them an attractive target for cancer immunotherapy
(Fig. 9A). Over the past years, NMR, X-ray and molecular
modelling-based studies have allowed building up a
structure-guided approach for the design of vaccines.92 The
combination of STD-NMR experiments with microarray bind-
ing experiments allowed the description of the epitope speci-
ficity of monoclonal antibodies against MUC1 and anti-Tn
MUC1. The study pinpointed how the amino acid sequence
and the sugar moiety are key factors modulating the binding
to the antibodies.93 In 2015, Corzana and co-workers reported
a detailed structural study regarding binding differences be-
tween α-O-GalNAc-Ser and -Thr MUC1-like glycopeptides.94
X-ray crystals with SM3, an anti-MUC1 antibody, revealed that
the glycosidic linkage of the bound Tn-Ser antigen and the
Fig. 8 Schematic representation of the employed approach to design
anti-HIV immunogenic glycopeptides.
Fig. 9 (A) Model of normal densely glycosylated MUC1 and tumor-
associated (TA) MUC1 with truncated glycosylation. (B) MUC1 synthetic
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Tn-Thr analogue featured different conformations, which fi-
nally impacts on their binding affinities. The Tn-Thr antigen,
which showed higher affinity, displayed quite restricted con-
formational flexibility and mainly populates a single confor-
mation both in solution and in the bound state. In contrast,
the low-affinity Tn-Ser antigen is more flexible and exhibits
different conformations around the glycosidic linkage. The
distinct conformational features of both –Ser and –Thr anti-
gens were deeply analysed and the key role of water molecules
was elucidated.95 The study of these glycopeptides in solution
and in the gas phase demonstrated the existence of a water
pocket between the sugar moiety and the peptide backbone
in the Tn-Thr antigen. GalNAc displayed a perpendicular ar-
rangement with respect to the amino acid chain and allowed
the accommodation of a water molecule, with important im-
plications for the receptor binding. These insights were essen-
tial, since the use of glycopeptides able to imitate the confor-
mational behaviour of cancer-associated MUC1 glycopeptides
must be advantageous for the design of potent vaccines.96
The enhanced potency of 2,3-sialyl-T antigen based vaccines
was also attributed to the improved turn-type conformation of
the glycopeptide bearing this specific carbohydrate epitope.97
Interestingly, the O/S or O/Se substitution at the glycosidic
linkage of MUC1 glycopeptides increases the affinity of the
corresponding mimetic antigens.98 The presence of S and Se
instead of an O atom increases the distance between the
sugar moiety and the peptide backbone and allows the pep-
tide to acquire a folded conformation, which is the optimum
for binding to the antibody. Unnatural modifications on the
peptide backbone were also successfully introduced in Tn-Thr
antigens and improved the binding affinity. The substitution
of proline by 4-fluoroproline or 4,4-difluoroproline at the most
immunogenic natural peptide sequence of MUC1 (APDTRP),
which strengthens the CH–π interactions with the antibody,
provided potent non-natural antigens (Fig. 9B).99
The use of unnatural glycopeptides not only improves re-
sistance against enzymatic degradation, but also overcomes
cancer immune escape mechanisms. Indeed, when the
S-glycoside mimetic carrying a fluoroproline was conjugated
to gold nanoparticles and administered to mice, it provided a
significant immune response, eliciting antibodies against
cancer-related natural MUC1 antigens. The combination with
immunostimulants is required for the activation of the T-cell-
dependent pathways and the production of high-affinity IgG
antibodies. Similarly, conjugation to carrier proteins, such as
tetanus toxoid, bovine serum albumin100 or bacterio-
phages,101 delivers potent MUC1 glycopeptide vaccines that
selectively target tumour-associated MUC1 on tumour cells
and not those on normal epithelial cells.
Carbohydrate-based vaccines
Carbohydrates with differentiating glycosylation patterns of
pathogens or malignant host cells could be used as antigens
for vaccine development.102 However, glycans in general are
poorly immunogenic and unable to elicit a T-cell memory re-
sponse. As a unique exception, polysaccharides with alternat-
ing positive and negative charges present at the surface of
some Gram-positive bacteria are able to activate T cells.103
Apart from this, vaccine development is usually achieved by
conjugation of glycan antigens to appropriate carriers such as
proteins, peptides or nanoparticles. In fact, chemical ligation
has an impact on the vaccine efficiency and different
methods have been developed.104 As described in the previous
section, tumor-associated carbohydrate antigens represent
specific targets for cancer immunotherapy, and vaccine de-
sign based on the synthetic modification of natural TACAs
has provided promising results showing potent responses
with reduced immunotolerance.105 Conjugates carrying bacte-
rial glycans have also been extensively employed for vaccine
preparation and the topic has been recently reviewed.106 Ini-
tially, the polysaccharide coats and major virulence factors of
bacteria were isolated from natural sources, and then chemi-
cally conjugated to carrier proteins. Although these vaccina-
tion agents were capable of eliciting a T-cell-dependent im-
mune response, the heterogeneity of the samples complicated
the manufacturing and introduced undesirable side effects.
More recently, the progress in carbohydrate chemistry and
methods to determine the immunogenic glycan epitopes107
has permitted the development of rationally designed anti-
bacterial and antifungal vaccines. However, bacterial patho-
gens such as Haemophilus influenza type b (Hib), Neisseria
meningitidis, and Streptococcus pneumoniae continue to cause
deadly diseases and the design of safe and highly efficacious
vaccines is still an active area of research. For instance,
Prevnar13 and Synflorix are currently employed pneumococ-
cal vaccines, though they only cover 13 and 10, respectively,
of more than 90 existing serotypes and consequently fail to of-
fer a wide coverage. In this regard, Seeberger and co-workers
have recently shown that glycoconjugates containing oligosac-
charides of different S. pneumoniae serotypes can be co-
formulated or used in combination with marketed vaccines to
generate a multivalent vaccine which induces a strong anti-
body response.108 Other novel approaches such as the use of
outer membrane vesicles109 or TL4 ligands as carriers110 are
being developed. Generally, such factors including the glycan
epitope, the carrier protein, the chemical ligation of the sugar
part or the activation mechanism of the immune system
make it difficult to rationalize the response to vaccines, and
thus, vaccine design results in a very challenging task. Inter-
estingly, it has been described that the polysaccharide struc-
ture influences the antigen processing and in turn the mecha-
nism underlying the adaptive immune response.111
Glycoproteins and therapeutic applications
The application of proteins as therapeutics in the pharmaceu-
tical field has been incredibly expanded over the past years,
proteins being one of the actual best-selling products for the
treatment of a wide range of diseases and pathologies. In this
regard, a great percentage of these proteins habitually display
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attachment is one of the most prominent structural changes.
More than half of the commercially available therapeutic pro-
teins are glycoproteins, which are obtained through molecular
biology protocols using living cell systems. Since the glycan
profile is essentially heterogeneous the recent research still
pursues the development and application of robust protocols
to analyse the glycan profile of both commercial and poten-
tially therapeutic glycoproteins,112–114 trying to better under-
stand how those different glycoforms affect the product qual-
ity in terms of effectiveness, stability, pharmacokinetics and
toxicity.115,116 Usually, the carbohydrate content of intact gly-
coproteins is directly assessed by chromatographic separation
coupled to mass spectrometry detection. Recently, a novel
workflow has been designed which uses relatively simple LC
or LC/MS methods to characterize complex glycosylated pro-
teins and antibodies at different levels (intact glycoprotein,
fragments cleaved by different proteases, released glycans).117
Even so, minor changes in the N-glycosylation pattern are dif-
ficult to detect in the extracted ion chromatograms. In this re-
gard, Planinc et al. have proposed an interesting approach
oriented to combine the sensitivity of MS detection devices
with subsequent principal component analysis (PCA) and
classification through soft independent modelling by class
analogy (SIMCA) that can be applied to the evaluation of pre-
viously released glycans via enzymatic cleavage.118 Lately, a
new and robust capillary electrophoresis-based method
coupled to ESI-MS has permitted the determination of the gly-
can content of diverse known mAbs, highlighting the repro-
ducibility and the accuracy of the results by comparison with
a HILIC-based reference method.119 Additionally, the applica-
bility of lectin microarrays120 to screen the glycans of thera-
peutic glycoproteins, especially monoclonal antibodies, has
also been highlighted.121
Monoclonal antibodies. Typically, monoclonal antibodies
are N-glycosylated at the residue Asn297, located on the CH2
domain of each heavy chain, and the type of structural sugars
may influence critical aspects on the mAb function.122 In-
deed, glycan heterogeneity accounts for the already known
asymmetrical binding of the Fc segment to the Fc receptors.
Moreover, the presence or absence of specific carbohydrates
may be either positive or negative for the engagement of the
corresponding Fcγ receptors (FcγR),123 and consequently, both
modifications could be exploited to improve the safety and ef-
ficacy of potentially commercial mAbs (Fig. 10).
For instance, reported evidence already exists about the ef-
fects of non-reducing galactose and fucose terminal residues
on the immune effector functions of antibodies.125 Recently,
an antibody constituted by a non-glycosylated F8-based
diabody has been engineered, in which each F8 unit is fused
via the C-terminus to a glycosylated interleukin-9 (IL9).126
With this system, Venetz and co-workers demonstrated that
variations in the N-linked glycans deeply changed the effi-
ciency of the F8 fragment to target the tumor cells. By quanti-
tative distribution analyses, they interestingly found a posi-
tive correlation between the level of sialylation in IL9
N-glycans and the capability of the F8 moiety to specifically
bind the spliced extradomain A (EDA) of fibronectin. Simi-
larly, the importance of controlling microheterogeneity in the
production of mAbs with therapeutic purposes has been
underlined. Indeed, it has been proposed that discrepancies
in efficiency and safety among mAbs could be explained by
differences in the surface charge of each glycoform as a con-
sequence of the existing heterogeneous glycan
environments.127
Preparation of homogenous glycoproteins. The enormous
importance of glycoproteins as therapeutics has led a lot of
research groups to keep improving existing protocols to ex-
press a given glycoprotein with the desired glycan profile. Al-
though non-mammalian hosts are available to be used as
well, like insect or yeast cells,128,129 Chinese hamster ovary
(CHO) cells are habitually the chosen expression systems for
preparing glycosylated proteins. However, glycan remodeling
is often mandatory in most cases to remove some non-human
epitopes that can lead to undesired side effects during the
therapy130 and to achieve glycan homogeneity. In general
terms, enzymatic glycoengineering is carried out by means of
glycosidases, glycosyltransferases and other enzymes to add
or remove certain monosaccharides or larger fragments
(Fig. 11A).131,132 Notably, endo-β-N-acetylglucosaminidases
(ENGases) are emerging as highly flexible and adaptable bio-
catalysts to afford homogeneous N-linked glycoproteins fol-
lowing a divergent biosynthetic scheme.133,134 The
glycosylated protein is normally produced by cell expression
and the incorporated glycans are later cleaved at the glyco-
sidic linkage between the first and the second GlcNAc moie-
ties (the inner chitobiose segment). Then, ENGases can be
conversely employed to catalyse the insertion of a custom oli-
gosaccharide chain into a single GlcNAc residue (Fig. 11B).132
Besides enzyme-based remodeling, special engineered
yeast strains with altered biosynthetic routes are likewise
used to afford mammalian-like glycans.135 A modified yeast
strain has been prepared by disparity mutagenesis, which is
glycosylation-deficient and exclusively produces high-
mannose-type N-glycans (Man9).136 An alternative strategy for
Fig. 10 Schematic representation of an IgG1 antibody structure (pdb
1HZH).124 Fab and Fc regions are indicated and the glycans present in
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glycoprotein preparation is total chemical synthesis or semi-
synthesis. Native chemical ligation (NCL) techniques allow
the chemoselective linkage of peptidic fragments through
coupling of a C-terminal thioester to an N-terminal cysteine
residue.137 This approach still has some important limita-
tions, especially for quite long proteins that would require
multiple ligations. The chemical lability of thioesters, also
subjected to epimerization equilibria, and the low percentage
of cysteine residues in protein sequences constitute the ma-
jor drawbacks. Consequently, and given the complexity and
variability of peptide fragments that may be needed, this area
of research remains under study and optimization. The use
of β-mercapto amino acid analogues instead of natural cyste-
ines, and the utilization of peptide hydrazides, which are
more stable, as substitutes for peptide thioesters are some of
the alternatives that have been described so far.138
Commercial glycoproteins. The list of commercial glyco-
proteins with therapeutic applications is incredibly large and
a high percentage of them are monoclonal antibodies. Some
of them, like erythropoietin (EPO) and Herceptin
(trastuzumab), are extensively used nowadays and remain part
of multiple research projects aimed at expanding and improv-
ing their applicability and effectiveness. EPO has been used
in the treatment of Alzheimer's disease due to its known
neuroprotective effects in rodent models. A fusion antibody
consisting of an EPO subunit attached to a chimeric monoclo-
nal antibody targeting the transferrin receptor (TfRMAb) has
been recently developed.139 With this design, the required
EPO dosage to achieve effectiveness was successfully reduced,
improving the penetration of this therapeutic mAb through
the blood–brain barrier (BBB). Analogously, these
neuroprotective properties of EPO also have promising appli-
cations for the treatment of traumatic brain injuries (TBIs) in
young patients. Recently, data from published randomized
controlled trials (RCTs) about the effectiveness of EPO for this
purpose have been described.140 Although the therapeutic ef-
fects in human patients with TBI have remained unclear over
the past years, it could be demonstrated, from a global per-
spective, that EPO treatment is not only safe for patients but
it also noticeably reduces the mortality rate of these patients.
In colon cancer, EPO has been reported to help in reducing
the growth rate of malignant cells when it is simultaneously
administered with LFM-A13, the inhibitor used to target
Bruton's tyrosine kinase (BTK), which is overexpressed in this
type of cancer.141 Herceptin, commercially known as
trastuzumab, is a glycosylated antibody used to treat early-
stage breast cancers. Rasaneh et al. have recently proposed a
novel method to increase the therapeutic efficiency of
Herceptin by linking this antibody to the surface of iron oxide
nanoparticles with magnetic properties.142 The results were
promising in mice, showing that the accumulation of these
Herceptin-loaded nanoparticles at the tumour tissues was effi-
ciently achieved in the presence of a magnetic field and led to
a slower tumour growth rate compared with Herceptin alone.
Similarly, conjugation of Herceptin to a macromolecular scaf-
fold has also been exploited to enhance the therapeutic effect
of cisplatin for tumour treatment.143 Making use of a func-
tionalized polyamidoamine dendrimer (PAMAM) bearing both
cisplatin and Herceptin, better therapeutic properties (lower
IC50 values, enhanced apoptosis) were observed in ovarian
cancer cell lines in comparison with free cisplatin or
dendrimers carrying cisplatin in the absence of Herceptin.
Conclusions
In the past years, many contributions have demonstrated that
the exploitation of carbohydrates in medicinal chemistry
opens a broad spectrum of therapeutic possibilities. Despite
the technical challenges associated with the intrinsic com-
plexity of glycans, tailor-made small glycomimetics have been
designed for blocking specific carbohydrate–lectin interac-
tions. The success of rationally driven approaches for the de-
velopment of new drugs is still to be widely demonstrated, al-
though it is clearly improving. In fact, several glycomimetics
are already in clinical trials. Nevertheless, more specific tar-
gets for glycomimetics still have to be uncovered. The enor-
mous progress in synthetic strategies, analytical tools and
high-resolution biophysical techniques has allowed advances
in the study of complex glycosylated structures, including gly-
coproteins. Dendrimers, nanoparticles and other polyvalent
structures have been introduced as a strategy to increase
avidity, not to mention the therapeutic potential of specifi-
cally designed glycopeptides. The development of
glycopeptide-based vaccines aimed to fight diseases such as
cancer or HIV is an active area of research. Similarly, potent
anti-bacterial vaccines have been developed. In this regard,
more attention should be paid to the mechanisms underlying
Fig. 11 Biosynthetic approaches for the preparation of homogeneous
glycoproteins. (A) Previous and post enzyme-based remodeling of the
overexpressed glycoforms. (B) Cleavage and subsequent incorporation
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the immune response, where the role of glycan epitopes re-
mains not fully understood. However, the awareness of the
key role of glycans also on the antibody effectiveness, stabil-
ity, pharmacokinetics and toxicity has broken the limits of
their therapeutic applications. Definitely, progress in glyco-
protein expression and their structural analysis is beginning
to overcome the challenge derived from the complexity of
large glycoconjugates. Furthermore, aspects directed to the
study of the cell-surface microenvironment effects are also
being addressed. Surely, the increasing understanding of all
aspects of glycoscience will allow the development of novel
and more effective therapies.
Conflicts of interest
There are no conflicts to declare.
Acknowledgements
We thank the European Research Council for financial
support (ERC-2017-AdG, project number 788143-RECGLYC-
ANMR). We also thank Instituto de Salud Carlos III of Spain,
ISCIII (grant PRB3 IPT17/0019 to A. G.) and Agencia Estatal
Investigación of Spain, AEI (grants CTQ2015-64597-C2-1-P and
RTI2018-094751-B-C21 and the Severo Ochoa Excellence Ac-
creditation SEV-2016-0644).
Notes and references
1 R. D. Cummings and M. E. Etzler, Essentials of
Glycobiology, ed. A. Varki, R. D. Cummings, J. D. Esko, H.
H. Freeze, P. Stanley, C. R. Bertozzi, G. W. Hart and M. E.
Etzler, Cold Spring Harbor (NY): Cold Spring Harbor
Laboratory Press, New York, 2nd edn, 2009, ch. 6.
2 A. Varki, Glycobiology, 2017, 27, 3–49.
3 C. Reily, T. J. Stewart, M. B. Renfrow and J. Novak, Nat. Rev.
Nephrol., 2019, 15, 346–366.
4 H. J. Joshi, Y. Narimatsu, K. T. Schjoldager, H. L. P. Tytgat,
M. Aebi, H. Clausen and A. Halim, Cell, 2018, 172, 632–632.
e2.
5 F. Schwarz and M. Aebi, Curr. Opin. Struct. Biol., 2011, 21,
576–582.
6 J. Nilsson, A. Halim, A. Grahn and G. Larson,
Glycoconjugate J., 2013, 30, 119–136.
7 (a) A. V. Everest-Dass, E. S. X. Moh, C. Ashwood, A. M. M.
Shathili and N. H. Packer, Expert Rev. Proteomics, 2018, 15,
165; (b) M. J. Kailemia, G. Xu, M. Wong, Q. Li, E.
Goonatilleke, F. Leon and C. B. Lebrilla, Anal. Chem.,
2018, 90, 208.
8 L. Krasnova and C.-H. Wong, J. Am. Chem. Soc., 2019, 1411,
3735–3754.
9 T. M. Puvirajesinghe and J. E. Turnbull,Microarrays, 2016, 5, 3.
10 J. Agirre, G. J. Davies, K. S. Wilson and K. D. Cowtan, Curr.
Opin. Struct. Biol., 2017, 44, 39–47.
11 (a) D. Sirohi, Z. Chen, L. Sun, T. Klose, T. C. Pierson, M. G.
Rossmann and R. J. Kuhn, Science, 2016, 352, 467–470; (b)
H. B. Gristick, H. Wang and P. J. Bjorkman, Acta
Crystallogr., Sect. D: Struct. Biol., 2017, 73, 822–828.
12 A. Ardá, H. Coelho, B. Fernández de Toro, S. Galante, A.
Gimeno, A. Poveda, J. Sastre, L. Unione, P. Valverde, F.
Javier Cañada and J. Jiménez-Barbero, Special Periodic
Reports. Carbohydrate Chemistry, ed. A. P. Rauter, T.
Lindhorst and Y. Queneau, RSC, 2017, ch. 2, vol. 42.
13 A. Ardá and J. Jiménez-Barbero, Chem. Commun., 2018, 54,
4761–4769.
14 A. Diniz, J. S. Dias, J. Jiménez-Barbero, F. Marcelo and E. J.
Cabrita, Chem. – Eur. J., 2017, 23, 13213–13220.
15 S. C. Purcell and K. Godula, Interface Focus, 2019, 9,
20180080.
16 E. Luchinat and L. Banci, IUCrJ, 2017, 4, 108–118.
17 (a) A. Fernández-Tejada, F. J. Cañada and J. Jiménez-
Barbero, ChemMedChem, 2015, 10, 1291–1295; (b) A.
Fernández-Tejada, F. J. Cañada and J. Jiménez-Barbero,
Chem. – Eur. J., 2015, 21, 10616–10628; (c) J. E. Hudak and
C. R. Bertozzi, Chem. Biol., 2014, 21, 16–37; (d) S. Cecioni,
A. Imberty and S. Vidal, Chem. Rev., 2015, 115, 525–561; (e)
M. Dalziel, M. Crispin, C. N. Scanlan, N. Zitzmann and
R. A. Dwek, Science, 2014, 343, 1235681; ( f ) R. Hevey,
Pharmaceuticals, 2019, 12, 55.
18 R. J. Linhardt, J. Med. Chem., 2003, 46, 2551–2564.
19 (a) M. Guerrini, D. Beccati, Z. Shriver, A. Naggi, K.
Viswanathan, A. Bisio, I. Capila, J. C. Lansing, S. Guglieri,
B. Fraser, A. Al-Hakim, N. S. Gunay, Z. Zhang, L. Robinson,
L. Buhse, M. Nasr, J. Woodcock, R. Langer, G.
Venkataraman, R. J. Linhardt, B. Casu, G. Torri and R.
Sasisekharan, Nat. Biotechnol., 2008, 26, 669–675; (b) D.
Keire, B. Mulloy, C. Chase, A. Al-Hakim, D. Cairatti, E.
Gray, J. Hogwood, T. Morris, P. Mourao, M. D. Soares and
A. Szajek, BioPharm Int., 2015, 28, 36–42.
20 S. Mohamed and D. R. Coombe, Pharmaceuticals, 2017, 10,
78.
21 J. M. Herbert, M. Petitou, J. C. Lormeau, R. Cariou, J.
Necciari, H. N. Magnani, P. Zandberg, R. G. M. van
Amsterdam, C. A. A. van Boeckel and D. G. Meuleman,
Cardiovasc. Drug Rev., 1997, 15, 1–26.
22 (a) D. Fisher, B. Xing, J. Dill, H. Li, H. H. Hoang, Z. Z.
Zhao, X. L. Yang, R. Bachoo, S. Cannon, F. M. Longo, M.
Sheng, J. Silver and S. X. Li, J. Neurosci., 2011, 31,
14051–14066; (b) Y. J. Shen, A. P. Tenney, S. A. Busch, K. P.
Horn, F. X. Cuascut, K. Liu, Z. G. He, J. Silver and J. G.
Flanagan, Science, 2009, 326, 592–596; (c) C. H. Coles, Y.
Shen, A. P. Tenney, C. Siebold, G. C. Sutton, W. Lu, J. T.
Gallagher, E. Y. Jones, J. G. Flanagan and A. R. Aricescu,
Science, 2011, 332, 484–488.
23 (a) Y. Ohtake and S. X. Li, Brain Res., 2015, 1619, 22–35; (b)
A. W. Stoker, Semin. Cell Dev. Biol., 2015, 37, 90–97.
24 X. Dai, W. Liu, Q. Zhou, C. Cheng, C. Yang, S. Wang, M.
Zhang, P. Tang, H. Song, D. Zhang and Y. Qin, J. Org.
Chem., 2016, 81(1), 162–184.
25 U. Bhaskar, E. Sterner, A. M. Hickey, A. Onishi, F. Zhang,


































































































1688 | Med. Chem. Commun., 2019, 10, 1678–1691 This journal is © The Royal Society of Chemistry 2019
26 S. Dey, H. Lo and C. H. Wong, J. Am. Chem. Soc., 2019, 141,
10309–10314.
27 (a) S. U. Hansen, G. J. Miller, G. C. Jayson and J. M.
Gardiner, Org. Lett., 2013, 15(1), 88–91; (b) S. U. Hansen,
G. J. Miller, M. J. Cliff, G. C. Jayson and J. M. Gardiner,
Chem. Sci., 2015, 6(11), 6158–6164.
28 (a) M. Baráth, S. U. Hansen, C. E. Dalton, G. C. Jayson, G. J.
Miller and J. M. Gardiner, Molecules, 2015, 20(4),
6167–6180; (b) S. Dey and C. H. Wong, Chem. Sci.,
2018, 9(32), 6685–6691.
29 C. Zong, A. Venot, O. Dhamale and G. J. Boons, Org. Lett.,
2013, 15(2), 342–345.
30 S. U. Hansen, G. J. Miller, C. Cole, G. Rushton, E.
Avizienyte, G. C. Jayson and J. M. Gardiner, Nat. Commun.,
2013, 4, 2016.
31 X. Zhang, V. Pagadala, H. M. Jester, A. M. Lim, T. Q. Pham,
A. P. Goulas, J. Liu and R. J. Linhardt, Chem. Sci.,
2017, 8(12), 7932–7940.
32 M. S. Lord, B. Cheng, F. Tang, J. G. Lyons, J. Rnjak-
Kovacina and J. M. Whitelock, Metab. Eng., 2016, 38,
105–114.
33 B. E. Stopschinski, B. B. Holmes, G. M. Miller, V. A. Manon,
J. Vaquer-Alicea, W. L. Prueitt, L. C. Hsieh-Wilson and M. I.
Diamond, J. Biol. Chem., 2018, 293(27), 10826–10840.
34 (a) E. Avizienyte, C. L. Cole, G. Rushton, G. J. Miller, A.
Bugatti, M. Presta, J. M. Gardiner and G. C. Jayson, PLoS
One, 2016, 11(8), e0159739; (b) G. J. Miller, S. U. Hansen, E.
Avizienyte, G. Rushton, C. L. Cole, G. C. Jayson and J. M.
Gardiner, Chem. Sci., 2013, 4, 3218–3222.
35 G. C. Jayson, S. U. Hansen, G. J. Miller, C. L. Cole, G.
Rushton, E. Avizienyte and J. M. Gardiner, Chem. Commun.,
2015, 51(72), 13846–13849.
36 C. Zong, R. Huang, E. Condac, Y. Chiu, W. Xiao, X. Li, W.
Lu, M. Ishahara, S. Wang, A. Ramiah, M. Stickney, P. Azadi,
I. J. Amster, K. W. Moremen, L. Wang, J. S. Sharp and G. J.
Boons, J. Am. Chem. Soc., 2016, 138(39), 13059–13067.
37 L. Unione, A. Gimeno, P. Valverde, I. Calloni, H. Coelho, S.
Mirabella, A. Poveda, A. Ardá and J. Jimenez-Barbero, Curr.
Med. Chem., 2017, 24, 4057–4080.
38 R. Sommer, S. Wagner, A. Varrot, C. M. Nycholat, A.
Khaledi, S. Häussler, J. C. Paulson, A. Imberty and A. Titz,
Chem. Sci., 2016, 7, 4990–5001.
39 S. Wang, L. Dupin, M. Noel, C. J. Carroux, L. Renaud, T.
Gehin, A. Meyer, E. Souteyrand, J. J. Vasseur, G. Vergoten,
Y. Chevolot, F. Morvana and S. Vidal, Chem. – Eur. J.,
2016, 22, 11785–11794.
40 K. Buffet, I. Nierengarten, N. Galanos, E. Gillon, M. Holler,
A. Imberty, S. E. Matthews, S. Vidal, S. P. Vincenta and J. F.
Nierengarten, Chem. – Eur. J., 2016, 22, 2955–2963.
41 G. Michaud, R. Visini, M. Bergmann, G. Salerno, R.
Bosco, E. Gillon, B. Richichi, C. Nativi, A. Imberty, A.
Stocker, T. Darbre and J.-L. Reymond, Chem. Sci., 2016, 7,
166–182.
42 R. Sommer, D. Hauck, A. Varrot, S. Wagner, A. Audfray, A.
Prestel, H. M. Mçller, A. Imberty and A. Titz,
ChemistryOpen, 2015, 4, 756–767.
43 R. Sommer, S. Wagner, K. Rox, A. Varrot, D. Hauck, E.-C.
Wamhoff, J. Schreiber, T. Ryckmans, T. Brunner, C.
Rademacher, R. W. Hartmann, M. Brönstrup, A. Imberty
and A. Titz, J. Am. Chem. Soc., 2018, 140, 2537–2545.
44 V. Denavit, D. Lainé, C. Bouzriba, E. Shanina, É. Gillon, S.
Fortin, C. Rademacher, A. Imberty and D. Giguère, Chem. –
Eur. J., 2019, 25, 4478–4490.
45 S. Wagner, D. Hauck, M. Hoffmann, R. Sommer, I.
Joachim, R. Müller, A. Imberty, A. Varrota and A. Titz,
Angew. Chem., Int. Ed., 2017, 56, 16559–16564.
46 J. Bouckaert, J. Berglund, M. Schembri, E. De Genst, L.
Cools, M. Wuhrer, C. S. Hung, J. Pinkner, R. Slattegard, A.
Zavialov, D. Choudhury, S. Langermann, S. J. Hultgren, L.
Wyns, P. Klemm, S. Oscarson, S. D. Knight and H. De
Greve, Mol. Microbiol., 2005, 55, 441–455.
47 (a) S. Kleeb, L. Pang, K. Mayer, D. Eris, A. Sigl, R. C.
Preston, P. Zihlmann, T. Sharpe, R. P. Jakob, D.
Abgottspon, A. S. Hutter, M. Scharenberg, X. Jiang, G.
Navarra, S. Rabbani, M. Smiesko, N. Ludin, J. Bezencon,
O. Schwardt, T. Maiera and B. Ernst, J. Med. Chem.,
2015, 58, 2221–2239; (b) C. Jarvis, Z. Han, V. Kalas, R.
Klein, J. S. Pinkner, B. Ford, J. Binkley, C. K.
Cusumano, Z. Cusumano, L. Mydock-McGrane, S. J.
Hultgren and J. W. Janetka, ChemMedChem, 2016, 11,
367–373.
48 W. Schönemann, J. Cramer, T. Mühlethaler, B. Fiege, M.
Silbermann, S. Rabbani, P. Dätwyler, P. Zihlmann, R. P.
Jakob, C. P. Sager, M. Smieško, O. Schwardt, T. Maier and
B. Ernst, ChemMedChem, 2019, 14, 749–757.
49 S. Kleeb, X. Jiang, P. Frei, A. Sigl, J. Bezencon, K.
Bamberger, O. Schwardt and B. Ernst, J. Med. Chem.,
2016, 59(7), 3163–3182.
50 C. P. Sager, B. Fiege, P. Zihlmann, R. Vannam, S. Rabbani,
R. P. Jakob, R. C. Preston, A. Zalewski, T. Maier, M. W.
Peczuh and B. Ernst, Chem. Sci., 2018, 9, 646–654.
51 P. Zihlmann, M. Silbermann, T. Sharpe, X. Jiang, T.
Mühlethaler, R. P. Jakob, S. Rabbani, C. P. Sager, P. Frei, T.
Maier and B. Ernst, Chem. – Eur. J., 2018, 24, 13049–13057.
52 J. Egger, C. Weckerle, B. Cutting, O. Schwardt, S. Rabbani,
K. Lemme and B. Ernst, J. Am. Chem. Soc., 2013, 135,
9820–9828.
53 K. E. Moog, M. Barz, M. Bartneck, F. Beceren-Braun, N.
Mohr, Z. Wu, L. Braun, J. Dernedde, E. A. Liehn, F. Tacke,
T. Lammers, H. Kunz and R. Zentel, Angew. Chem., Int. Ed.,
2016, 55, 1416–1421.
54 T. Angata, C. M. Nycholat and M. S. Macauley, Trends
Pharmacol. Sci., 2015, 36, 645–660.
55 C. Büll, T. Heise, G. J. Adema and T. J. Boltje, Trends
Biochem. Sci., 2016, 41, 519–531.
56 J. Ereño-Orbea, T. Sicard, H. Cui, M. T. Mazhab-Jafari, S.
Benlekbir, A. Guarné, J. L. Rubinstein and J.-P. Julien, Nat.
Commun., 2017, 8, 764.
57 H. Prescher, A. Schweizer, E. Kuhfeldt, L. Nitschke and R.
Brossmer, ChemBioChem, 2017, 18, 1216–1225.


































































































Med. Chem. Commun., 2019, 10, 1678–1691 | 1689This journal is © The Royal Society of Chemistry 2019
59 (a) H. Feinberg, R. Castelli, K. Drickamer, P. H. Seeberger
and W. I. Weis, J. Biol. Chem., 2007, 282, 4202–4209; (b) A.
Holla and A. Skerra, Protein Eng., Des. Sel., 2011, 24,
659–669; (c) K. Brzezicka, B. Echeverria, S. Serna, A. Van
Diepen, C. H. Hooke and N.-C. Reichardt, ACS Chem. Biol.,
2015, 10, 1290–1302; (d) K. Pederson, D. A. Mitchell and
J. H. Prestegard, Biochemistry, 2014, 53, 5700–5709; (e) J. D.
Martínez, P. Valverde, S. Delgado, C. Romanò, B. Linclau,
N. C. Reichardt, S. Oscarson, A. Ardá, J. Jiménez-Barbero
and F. J. Cañada, Molecules, 2019, 24, E2337; ( f ) P.
Valverde, S. Delgado, J. D. Martínez, J.-B. Vendeville, B.
Linclau, J. Malassis, N. C. Reichardt, F. J. Cañada, J.
Jiménez-Barbero and A. Ardá, ACS Chem. Biol., 2019, 14,
1660–1671.
60 J. Aretz, H. Baukmann, E. Shanina, J. Hanske, R.
Wawrzinek, V. A. Zapolśkii, P. H. Seeberger, D. E.
Kaufmann and C. Rademacher, Angew. Chem., Int. Ed.,
2017, 56, 7292–7296.
61 V. Porkolab, E. Chabrol, N. Varga, S. Ordanini, I.
Sutkevičiūtė, M. Thepau, M. J. Garcia-Jimenez, E. Girard,
P. M. Nieto, A. Bernardi and F. Fieschi, ACS Chem. Biol.,
2018, 13, 600.
62 (a) B. Bertolotti, I. Sutkeviciute, M. Ambrosini, R.
Ribeiro-Viana, J. Rojo, F. Fieschi, H. Dvořáková, M.
Kašáková, K. Parkan, M. Hlaváčková, K. Nováková and J.
Moravcová, Org. Biomol. Chem., 2017, 15, 3995; (b) S.
Ordanini, N. Varga, V. Porkolab, M. Thépaut, L. Belvisi,
A. Bertaglia, A. Palmioli, A. Berzi, D. Trabattoni, M.
Clerici, F. Fieschi and A. Bernardi, Chem. Commun.,
2015, 51, 3816; (c) A. Berzi, S. Ordanini, B. Joosten, D.
Trabattoni, A. Cambi, A. Bernardi and M. Clerici, Sci.
Rep., 2016, 6, 35373.
63 Y. Guo, I. Nehlmeier, E. Poole, C. Sakonsinsiri, N. Hondow,
A. Brown, Q. Li, S. Li, J. Whitworth, Z. Li, A. Yu, R. Brydson,
W. B. Turnbull, S. Pöhlmann and D. Zhou, J. Am. Chem.
Soc., 2017, 139, 11833–11844.
64 L. Johannes, R. Jacob and H. Leffler, J. Cell Sci., 2018, 131,
jcs208884.
65 R. P. M. Dings, M. C. Miller, R. J. Griffin and K. H. Mayo,
Int. J. Mol. Sci., 2018, 19, 905.
66 A. Girard and J. L. Magnani, Trends Glycosci. Glycotechnol.,
2018, 30, SE211–SE220.
67 H. Blanchard, X. Yu, P. M. Collins and K. Bum-Erdene,
Expert Opin. Ther. Pat., 2014, 24, 1053–1065.
68 V. L. Campo, M. F. Marchiori, L. C. Rodrigues and M. Dias-
Baruffi, Glycoconjugate J., 2016, 3, 853–876.
69 D. Laaf, P. Bojarová, L. Elling and V. Kren, Trends
Biotechnol., 2019, 37, 402–415.
70 A. Gimeno, S. Delgado, P. Valverde, S. Bertuzzi, M. A.
Berbis, J. Echavarren, A. Lacetera, S. Martín-
Santamaria, A. Surolia, F. J. Cañada, J. Jimenez-
Barbero and A. Ardá, Angew. Chem., Int. Ed., 2019, 58,
7268–7272.
71 S. Santarsia, A. S. Grosso, F. Trovão, J. Jiménez-Barbero,
A. L. Carvalho, C. Nativi and F. Marcelo, ChemMedChem,
2018, 13, 2030–2036.
72 F. Manzoni, J. Wallerstein, T. E. Schrader, A. Ostermann, L.
Coates, M. Akke, M. P. Blakeley, E. Oksanen and D. T.
Logan, J. Med. Chem., 2018, 61, 4412–4420.
73 R. Tellez-Sanz, L. García-Fuentes and A. Vargas-Berenguel,
Curr. Med. Chem., 2013, 20, 2979–2990.
74 I. Cumpstey, A. Sundin, H. Leffler and U. J. Nilsson, Angew.
Chem., Int. Ed., 2005, 44, 5110–5112.
75 T. Delaine, P. Collins, A. MacKinnon, G. Sharma, J.
Stegmayr, V. K. Rajput, S. Mandal, I. Cumpstey, A.
Larumbe, B. A. Salameh, B. Kahl-Knutsson, H. van Hattum,
M. V. Scherpenzeel, R. J. Pieters, T. Sethi, H. Schambye, S.
Oredsson, H. Leffler, H. Blanchard and U. J. Nilsson,
ChemBioChem, 2016, 17, 1759–1770.
76 T.-J. Hsieh, H.-Y. Lin, Z. Tu, T.-C. Lin, S.-C. Wu, Y.-Y. Tseng,
F.-T. Liu, S.-T. D. Hsu and C.-H. Lin, Sci. Rep., 2016, 6,
29457.
77 V. K. Rajput, A. MacKinnon, S. Mandal, P. Collins, H.
Blanchard, H. Leffler, T. Sethi, H. Schambye, B.
Mukhopadhyay and U. J. Nilsson, J. Med. Chem., 2016, 59,
8141–8147.
78 F. R. Zetterberg, K. Peterson, R. E. Johnsson, T. Brimert, M.
Håkansson, D. T. Logan, H. Leffler and U. J. Nilsson,
ChemMedChem, 2018, 13, 133–137.
79 A. Dahlqvist, F. R. Zetterberg, H. Leffler and U. J. Nilsson,
Med. Chem. Commun., 2019, 10, 913–925.
80 K. Peterson, R. Kumar, O. Stenström, P. Verma, P. R.
Verma, M. Hakansson, B. Kahl-Knutsson, F. Zetterberg, H.
Leffler, M. Akke, D. T. Logan and U. J. Nilsson, J. Med.
Chem., 2018, 61, 1164–1175.
81 M. A. T. Blaskovich, K. A. Hansford, M. S. Butler, Z. Jia,
A. E. Mark and M. A. Cooper, ACS Infect. Dis., 2018, 4,
715–735.
82 V. Kren and T. Rezanka, FEMS Microbiol. Rev., 2008, 32,
858–889.
83 J. Kaplan, B. D. Korty, P. H. Axelsen and P. J. Loll, J. Med.
Chem., 2001, 44, 1837–1840.
84 S. Ng, E. Lin, P. I. Kitov, K. F. Tjhung, O. O. Gerlits, L.
Deng, B. Kasper, A. Sood, B. M. Paschal, P. Zhang, C.-C.
Ling, J. S. Klassen, C. J. Noren, L. K. Mahal, R. J. Woods, L.
Coates and R. Derda, J. Am. Chem. Soc., 2015, 137,
5248–5251.
85 S. Behren and U. Westerlind, Molecules, 2019, 24, 100.
86 (a) M. Bergmann, G. Michaud, R. Visini, X. Jin, E. Gillon, A.
Stocker, A. Imberty, T. Darbre and J.-L. Reymond, Org.
Biomol. Chem., 2016, 14, 138–148; (b) G. Michaud, R. Visini,
M. Bergmann, G. Salerno, R. Bosco, E. Gillon, B. Richichi,
C. Nativi, A. Imberty, A. Stocker, T. Darbre and J.-L.
Reymond, Chem. Sci., 2016, 7, 166–182.
87 C. Bonduelle, H. Oliveira, C. Gauche, J. Huang, A. Heise
and S. Lecommandoux, Chem. Commun., 2016, 52,
11251–11254.
88 S.-F. Huang, C.-H. Lin, Y.-T. Lai, C.-L. Tsai, T.-J. R. Cheng
and S.-K. Wang, Chem. – Asian J., 2018, 13, 686–700.
89 H. Cai, J. Orwenyo, J. P. Giddens, Q. Yang, R. Zhang, C. C.
LaBranche, D. C. Montefiori and L.-X. Wang, Cell Chem.

































































































1690 | Med. Chem. Commun., 2019, 10, 1678–1691 This journal is © The Royal Society of Chemistry 2019
90 H. Cai, R. Zhang, J. Orwenyo, J. P. Giddens, Q. Yang, C. C.
LaBranche, D. Montefiori and L.-X. Wang, J. Med. Chem.,
2018, 61, 10116–10125.
91 A. Escolano, H. B. Gristick, M. E. Abernathy, J.
Merkenschlager, R. Gautam, T. Y. Oliveira, J. Pai, A. P. West
Jr, C. O. Barnes, A. A. Cohen, H. Wang, J. Golijanin, D.
Yost, J. R. Keeffe, Z. Wang, P. Zhao, K. Yao, J. Bauer, L.
Nogueira, H. Gao, A. V. Voll, D. C. Montefiori, M. S.
Seaman, A. Gazumyan, M. Silva, A. T. McGuire, L.
Stamatatos, D. J. Irvine, L. Wells, M. A. Martin, P. J.
Bjorkman and M. C. Nussenzweig, Nature, 2019, 570,
468–473.
92 N. Martínez-Sáez, J. M. Peregrina and F. Corzana, Chem.
Soc. Rev., 2017, 46, 7154–7175.
93 H. Coelho, T. Matsushita, G. Artigas, H. Hinou, F. J.
Cañada, R. Lo-Man, C. Leclerc, E. J. Cabrita, J. Jiménez-
Barbero, S.-I. Nishimura, F. Garcia-Martín and F. Marcelo,
J. Am. Chem. Soc., 2015, 137, 12438–12441.
94 N. Martínez-Sáez, J. Castro-López, J. Valero-González, D.
Madariaga, I. Compañón, V. J. Somovilla, M. Salvadó, J. L.
Asensio, J. Jiménez-Barbero, A. Avenoza, J. H. Busto, G. J. L.
Bernardes, J. M. Peregrina, R. Hurtado-Guerrero and F.
Corzana, Angew. Chem., 2015, 127, 9968–9972.
95 I. A. Bermejo, I. Usabiaga, I. Compañón, J. Castro-López, A.
Insausti, J. A. Fernandez, A. Avenoza, J. H. Busto, J.
Jiménez-Barbero, J. L. Asensio, J. M. Peregrina, G. Jiménez-
Osés, R. Hurtado-Guerrero, E. J. Cocinero and F. Corzana,
J. Am. Chem. Soc., 2018, 140, 9952–9960.
96 N. Martínez-Sáez, N. T. Supekar, M. A. Wolfert, I. A.
Bermejo, R. Hurtado-Guerrero, J. L. Asensio, J. Jiménez-
Barbero, J. H. Busto, A. Avenoza, G.-J. Boons, J. M.
Peregrina and F. Corzana, Chem. Sci., 2016, 7, 2294–2301.
97 D. Straßburger, M. Glaffig, N. Stergiou, S. Bialas, P.
Besenius, E. Schmitt and H. Kunz, ChemBioChem, 2018, 19,
1142–1146.
98 I. Compañón, A. Guerreiro, V. Mangini, J. Castro-López, M.
Escudero-Casao, A. Avenoza, J. H. Busto, S. Castillón, J.
Jiménez-Barbero, J. L. Asensio, G. Jiménez-Osés, O.
Boutureira, J. M. Peregrina, R. Hurtado-Guerrero, R.
Fiammengo, G. J. L. Bernardes and F. Corzana, J. Am.
Chem. Soc., 2019, 141, 4063–4072.
99 V. J. Somovilla, I. A. Bermejo, I. S. Albuquerque, N.
Martínez-Sáez, J. Castro-López, F. Garcia Martin, I.
Compañón, H. I. Hinou, S.-I. Nishimura, J. Jiménez-
Barbero, J. L. Asensio, A. Avenoza, J. H. Busto, R. Hurtado-
Guerrero, J. M. Peregrina, G. J. L. Bernardes and F.
Corzana, J. Am. Chem. Soc., 2017, 139, 18255–18261.
100 B. Palitzsch, N. Gaidzik, N. Stergiou, S. Stahn, S. Hartmann,
B. Gerlitzki, N. Teusch, P. Flemming, E. Schmitt and H.
Kunz, Angew. Chem., Int. Ed., 2016, 55, 2894–2898.
101 X. Wu, Z. Yin, C. McKay, C. Pett, J. Yu, M. Schorlemer, T.
Gohl, S. Sungsuwan, S. Ramadan, C. Baniel, A. Allmon, R.
Das, U. Westerlind, M. G. Finn and X. Huang, J. Am. Chem.
Soc., 2018, 140, 16596–16609.
102 M. A. Wolfert and G.-J. Boons, Nat. Chem. Biol., 2013, 9,
776–784.
103 L. Sun, D. R. Middleton, P. L. Wantuch, A. Ozdilek and
F. Y. Avic, Glycobiology, 2016, 26, 1029–1040.
104 F. Berti and R. Adamo, Chem. Soc. Rev., 2018, 47,
9015–9025.
105 (a) T.-C. Chang, Y. Manabe, Y. I. Fujimoto, S. Ohshima, Y.
Kametani, K. Kabayama, Y. Nimura, C.-C. Lin and K. I.
Fukase, Angew. Chem., Int. Ed., 2018, 57, 8219–8224; (b)
M.-M. Wei, Y. S. Wang and X. S. Ye, Med. Res. Rev.,
2018, 38, 1003–1026.
106 (a) C. Colombo, O. Pitirollo and L. Lay, Molecules, 2018, 23,
1712; (b) S. A. Krumm and K. J. Doores, Current Topics in
Microbiology and Immunology, Springer, Berlin, Heidelberg,
2018; (c) J. Hütter and B. Lepenies, Methods Mol. Biol.,
2015, 1331, 1–10.
107 C. L. Anish, B. Schumann, C. L. Pereira and P. H.
Seeberger, Chem. Biol., 2014, 21, 38–50.
108 P. Kaplonek, N. Khan, K. Reppe, B. Schumann, M.
Emmadi, M. P. Lisboa, F.-F. Xu, A. D. J. Calow, S. G.
Parameswarappa, M. Witzenrath, C. L. Pereira and P. H.
Seeberger, Proc. Natl. Acad. Sci. U. S. A., 2018, 115,
13353–13358.
109 (a) T. C. Stevenson, C. Cywes-Bentley, T. D. Moeller, K. B.
Weyant, D. Putnam, Y.-F. Chang, B. D. Jones, G. B. Pier and
M. P. DeLisa, Proc. Natl. Acad. Sci. U. S. A., 2018, 115,
E3106–E3115; (b) F. Micoli, S. Rondini, R. Alfini, L.
Lanzilao, F. Necchi, A. Negrea, O. Rossi, C. Brandt, S. Clare,
P. Mastroeni, R. Rappuoli, A. Saul and C. A. MacLennan,
Proc. Natl. Acad. Sci. U. S. A., 2018, 115, 10428–10433.
110 Q. Li and Z. Guo, Molecules, 2018, 23, 1583.
111 X. Sun, G. Stefanetti, F. Berti and D. L. Kasper, Proc. Natl.
Acad. Sci. U. S. A., 2019, 116, 193–198.
112 S. Carillo, S. Mittermayr, A. Farrell, S. Albrecht and J.
Bones, Methods Mol. Biol., 2017, 1603, 227–241.
113 B. Bobaly, V. D'Atri, A. Goyon, O. Colas, A. Beck, S. Fekete
and D. Guillarme, J. Chromatogr. B: Anal. Technol. Biomed.
Life Sci., 2017, 1060, 325–335.
114 A. Resemann, W. Jabs, A. Wiechmann, E. Wagner, O. Colas,
W. Evers, E. Belau, L. Vorwerg, C. Evans, A. Beck and D.
Suckau, mAbs, 2016, 8, 318–330.
115 D. Reusch and M. L. Tejada, Glycobiology, 2015, 25,
1325–1334.
116 L. Liu, J. Pharm. Sci., 2015, 104, 1866–1884.
117 E. Largy, F. Cantais, G. Van Vyncht, A. Beck and A. Delobel,
J. Chromatogr. A, 2017, 1498, 128–146.
118 A. Planinc, B. Dejaegher, Y. V. Heyden, J. Viaene, S. Van
Praet, F. Rappez, P. Van Antwerpen and C. Delporte, Anal.
Bioanal. Chem., 2017, 409, 477–485.
119 J. Giorgetti, V. D'Atri, J. Canonge, A. Lechner, D. Guillarme,
O. Colas, E. Wagner-Rousset, A. Beck, E. Leize-Wagner and
Y. François, Talanta, 2018, 178, 530–537.
120 L. Zhang, S. Luo and B. Zhang, mAbs, 2016, 8, 205–215.
121 L. Zhang, S. Luo and B. Zhang, mAbs, 2016, 8, 524–535.
122 F. Cymera, H. Beck, A. Rohde and D. Reusch, Biologicals,
2018, 52, 1–11.
123 F. Higel, A. Seidl, F. Sörgel and W. Friess, Eur. J. Pharm.

































































































Med. Chem. Commun., 2019, 10, 1678–1691 | 1691This journal is © The Royal Society of Chemistry 2019
124 E. O. Saphire, P. W. H. I. Parren, R. Pantophlet, M. B.
Zwick, G. M. Morris, P. M. Rudd, R. A. Dwek, R. L.
Stanfield, D. R. Burton and L. A. Wilson, Science, 2001, 293,
1155–1159.
125 W. Li, Z. Zhu, W. Chen, Y. Feng and D. S. Dimitrov, Front.
Immunol., 2017, 8, 1554.
126 D. Venetz, C. Hess, C. Lin, M. Aebi and D. Neri, Proc. Natl.
Acad. Sci. U. S. A., 2015, 112(7), 2000–2005.
127 B. Hintersteiner, N. Lingg, E. Janzek, O. Mutschlechner, H.
Loibner and A. Jungbauer, Biotechnol. J., 2016, 11(12), 1617–1627.
128 A. W. Barb, D. J. Falconer and G. P. Subedi, Methods
Enzymol., 2019, 614, 239–261.
129 S. Yanaka, H. Yagi, R. Yogo, M. Y. Utsumi and K. Kato,
J. Biomol. NMR, 2018, 71, 193–202.
130 M. Dicker and R. Strasser, Expert Opin. Biol. Ther.,
2015, 15(10), 1501–1516.
131 Q. Yang and L. Wang, Methods Enzymol., 2017, 597,
265–281.
132 Y. Mimura, T. Kato, R. Saldova, R. O'Flaherty, T. Izumi, Y.
Mimura-Kimura, T. Utsunomiya, Y. Mizukami, K.
Yamamoto, T. Matsumoto and P. M. Rudd, Protein Cell,
2018, 9, 47–62.
133 A. J. Fairbanks, Chem. Soc. Rev., 2017, 46, 5128–5146.
134 T. B. Parsons, W. B. Struwe, J. Gault, K. Yamamoto, T. A.
Taylor, R. Raj, K. Wals, S. Mohammed, C. V. Robinson,
J. L. P. Benesch and B. G. Davis, Angew. Chem., Int. Ed.,
2016, 55, 2361–2367.
135 T. Nagasu, Y. Shimma, Y. Nakanishi, J. Kuromitsu, K.
Iwama, K. Nakayama, K. Suzuki and Y. Jigami, Yeast,
1992, 8, 535–547.
136 H. Abe, Y. Takaoka, Y. Chiba, N. Sato, S. Ohgiya, A. Itadani,
M. Hirashima, C. Shimoda, Y. Jigami and K. Nakayama,
Glycobiology, 2009, 19, 428–436.
137 C. Unverzagt and Y. Kajihara, Curr. Opin. Chem. Biol.,
2018, 46, 130–137.
138 G.-M. Fang, Y.-M. Li, F. Shen, Y.-C. Huang, J.-B. Li, Y. Lin,
H.-K. Cui and L. Liu, Angew. Chem., Int. Ed., 2011, 50,
7645–7649.
139 R. Chang, A. Al Maghribi, V. Vanderpoel, A. Ing, V.
Vasilevko, D. H. Cribbs, R. Boado, W. M. Pardridge
and R. Sumbria, Alzheimer's Dementia, 2018, 14,
1086–1087.
140 W. Liu, L. Wen, T. Xie, H. Wang, J. Gong and X. Yang,
J. Neurosurg., 2016, 127, 1–8.
141 A. Tankiewicz-Kwedlo, J. M. Hermanowicz, T.
Domaniewski, K. Pawlak, M. Rusak, A. Pryczynicz, A.
Surazynski, T. Kaminski, A. Kazberuk and D. Pawlak, Br. J.
Pharmacol., 2018, 175, 743–762.
142 S. Rasaneh and M. R. Dadras, Biomed. Tech., 2015, 60,
485–490.
143 A. Kesavan, P. Ilaiyaraja, W. S. Beaula, V. V. Kumari, J. S.
Lal, C. Arunkumar, G. Anjana, S. Srinivas, A. Ramesh, S. K.
Rayala, D. Ponraju and G. Venkatraman, Eur. J. Pharm.
Biopharm., 2015, 96, 255–263.
MedChemComm Review
O
pe
n 
A
cc
es
s 
A
rt
ic
le
. P
ub
lis
he
d 
on
 2
6 
Ju
ly
 2
01
9.
 D
ow
nl
oa
de
d 
on
 1
2/
2/
20
19
 6
:4
2:
24
 P
M
. 
 T
hi
s 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
C
om
m
on
s 
A
ttr
ib
ut
io
n-
N
on
C
om
m
er
ci
al
 3
.0
 U
np
or
te
d 
L
ic
en
ce
.
View Article Online
